[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 423,482
  • Shares Outstanding, K 80,205
  • Annual Sales, $ 0 K
  • Annual Income, $ -158,350 K
  • EBIT $ -184 M
  • EBITDA $ -188 M
  • 60-Month Beta 0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.05

Options Overview Details

View History
  • Implied Volatility 118.83% (+17.39%)
  • Historical Volatility 45.50%
  • IV Percentile 16%
  • IV Rank 7.80%
  • IV High 737.60% on 02/13/26
  • IV Low 66.45% on 09/02/25
  • Expected Move (DTE 2) 0.47 (8.36%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 104
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 7,574
  • Open Int (30-Day) 6,994
  • Expected Range 5.12 to 6.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.50
  • Number of Estimates 2
  • High Estimate $-0.42
  • Low Estimate $-0.59
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) +5.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.82 +46.34%
on 07/28/26
5.61 -0.36%
on 08/19/26
+0.72 (+14.78%)
since 07/17/26
3-Month
3.82 +46.34%
on 07/28/26
5.61 -0.36%
on 08/19/26
+1.44 (+34.70%)
since 05/19/26
52-Week
2.78 +101.08%
on 10/02/25
6.45 -13.33%
on 03/10/26
+2.10 (+60.17%)
since 08/19/25

Most Recent Stories

More News
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Reports Tomorrow With Its Antiviral Pipeline Still Waiting for Commercial Validation

Barchart Research What to Expect from AVIR Earnings AVIR Generated August 11, 2026 Current Price $5.05 EPS Estimate $$-0.56 Consensus Rating Moderate Buy Average Move 7.90% Atea Pharmaceuticals Reports...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Reports Earnings After Its Stock Lost Half Its Value This Quarter

Barchart Research What to Expect from AVIR Earnings AVIR Generated August 5, 2026 Current Price $4.75 EPS Estimate $$-0.56 Consensus Rating Moderate Buy Average Move 7.90% Atea Pharmaceuticals Reports...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral...

AVIR : 5.59 (+5.87%)
Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved...

AVIR : 5.59 (+5.87%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 5.94
2nd Resistance Point 5.77
1st Resistance Point 5.68
Last Price 5.59
1st Support Level 5.43
2nd Support Level 5.26
3rd Support Level 5.17

See More

52-Week High 6.45
Last Price 5.59
Fibonacci 61.8% 5.05
Fibonacci 50% 4.61
Fibonacci 38.2% 4.18
52-Week Low 2.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.